Lantern Pharma Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Lantern Pharma Inc. on October 20, 2023, reporting an event that occurred on October 17, 2023. The company is a Delaware corporation with its principal executive offices in Dallas, Texas, and its common stock trades on The Nasdaq Stock Market under the symbol LTRN.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current report regarding a specific corporate event and does not contain financial statements or performance metrics.
Material Changes
The material change reported is the unexpected death of Dr. Franklyn Prendergast, a member of the Company's Board of Directors. Dr. Prendergast had served as a director since October 2019.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of risks and contingencies beyond the announcement of the director's passing. The Company expressed deep regret regarding the event.
Key Facts for Investors to Verify
- Confirmation of the appointment of a new director to fill the vacancy left by Dr. Prendergast.
- Any potential impact on the Company's strategic direction or board composition.
- Subsequent filings regarding the status of the Board of Directors.